Scilex Holding Company (SCLXW)Palo Alto, United States | NasdaqCM
0.19 USD
-0.02
(-7.242%) ⇩
(July 13, 2026, 2:05 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 4:47 a.m. EDT
The security is trading at a negligible price of roughly $0.21 against a negative book value of -$35.44, indicating a complete erosion of shareholder equity and a total loss of intrinsic value. Fundamentals are catastrophic: operating cash flow is negative ($3.3M), return on assets is deeply negative (-92%), and the company carries massive debt ($106M) against minimal cash ($3.3M). While revenue growth shows a theoretical 72% increase, this is meaningless in the face of insolvency and negative margins. With no price history available to assess momentum or long-term trajectory, and absolutely no dividend capability given the financial distress, this instrument represents a high-risk speculative wager rather than an investment. |
| Attribute | Value |
|---|---|
| Revenue per Share | 3.432 |
| Beta | 1.73 |
| Website | https://www.scilexholding.com |
| Attribute | Value |
|---|---|
| Address1 | 960 San Antonio Road |
| Ask | 0.0 |
| Ask Size | 0 |
| Beta | 1.727 |
| Bid | 0.0 |
| Bid Size | 0 |
| Book Value | -35.436 |
| City | Palo Alto |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.1947 |
| Current Ratio | 0.084 |
| Custom Price Alert Confidence | HIGH |
| Day High | 0.21 |
| Day Low | 0.1947 |
| Display Name | Scilex Holding |
| Ebitda | -270,086,016 |
| Ebitda Margins | 0.0 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Two Week High | 0.21 |
| Fifty Two Week High Change | -0.015299991 |
| Fifty Two Week High Change Percent | -0.072857104 |
| Fifty Two Week Low | 0.1947 |
| Fifty Two Week Low Change | 0.0 |
| Fifty Two Week Low Change Percent | 0.0 |
| Fifty Two Week Range | 0.1947 - 0.21 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,783,690,200,000 |
| Float Shares | 5,686,535 |
| Free Cashflow | 5,986,500 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 34 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.59654 |
| Gross Profits | 20,200,000 |
| Has Pre Post Market Data | 1 |
| Industry | |
| Industry Key | |
| Language | en-US |
| Long Business Summary | Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA; and Tulex Master, which develops, tests, and manufactures clinical supplies of SP-104. Scilex Holding Company is based in Palo Alto, California. |
| Long Name | Scilex Holding Company |
| Market | us_market |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_607715156 |
| Net Income To Common | -419,676,992 |
| Open | 0.17 |
| Operating Cashflow | -3,298,000 |
| Operating Margins | -3.7349398 |
| Phone | 650 516 4310 |
| Previous Close | 0.2099 |
| Price Hint | 4 |
| Price To Book | -0.0054944125 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.066 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.015200004 |
| Regular Market Change Percent | -7.2415457 |
| Regular Market Day High | 0.21 |
| Regular Market Day Low | 0.1947 |
| Regular Market Day Range | 0.1947 - 0.21 |
| Regular Market Open | 0.17 |
| Regular Market Previous Close | 0.2099 |
| Regular Market Price | 0.1947 |
| Regular Market Time | 1,783,965,939 |
| Regular Market Volume | 3,257 |
| Return On Assets | -0.92783 |
| Revenue Growth | 0.721 |
| Revenue Per Share | 3.432 |
| Sand P52 Week Change | 0.20847368 |
| Sector | |
| Sector Key | |
| Source Interval | 15 |
| State | CA |
| Symbol | SCLXW |
| Total Cash | 3,361,000 |
| Total Cash Per Share | 0.478 |
| Total Debt | 106,359,000 |
| Total Revenue | 33,862,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Type Disp | Equity |
| Volume | 3,257 |
| Website | https://www.scilexholding.com |
| Zip | 94,303 |